D. E. Shaw & Co. Inc. boosted its position in Omeros Co. (NASDAQ:OMER) by 49.5% during the 4th quarter, HoldingsChannel reports. The fund owned 1,912,244 shares of the biopharmaceutical company’s stock after buying an additional 632,840 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Omeros were worth $21,303,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the business. Freestone Capital Holdings LLC purchased a new stake in shares of Omeros in the third quarter worth approximately $285,000. Man Group plc purchased a new stake in shares of Omeros in the third quarter worth approximately $286,000. Advisors Asset Management Inc. purchased a new stake in shares of Omeros in the third quarter worth approximately $301,000. Rocky Mountain Advisers LLC raised its stake in shares of Omeros by 8.5% in the fourth quarter. Rocky Mountain Advisers LLC now owns 12,760 shares of the biopharmaceutical company’s stock worth $142,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Keeley Teton Advisors LLC raised its stake in shares of Omeros by 8.9% in the fourth quarter. Keeley Teton Advisors LLC now owns 13,001 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 1,060 shares during the last quarter. Institutional investors and hedge funds own 48.89% of the company’s stock.
Shares of OMER opened at $17.72 on Friday. The company has a market cap of $860.65 million, a P/E ratio of -7.98 and a beta of 3.58. Omeros Co. has a 12 month low of $10.30 and a 12 month high of $27.00.
OMER has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Omeros in a research note on Tuesday, December 4th. Maxim Group set a $32.00 price objective on Omeros and gave the stock a “buy” rating in a research note on Thursday, December 6th. ValuEngine downgraded Omeros from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Zacks Investment Research downgraded Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday, February 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Omeros has a consensus rating of “Buy” and a consensus price target of $35.00.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Article: How to interpret a stock’s beta number
Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Co. (NASDAQ:OMER).
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.